MDP.T

Vancouver’s own Jody Vance speaks with Ken d’Entremont, Medexus Pharmaceuticals (MDP.V) CEO and director, to find out more about the company’s mandate of bringing established drugs approved in other…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Cancer is a bitch. Even if you haven’t had to battle against cancer yourself, you likely know someone who has. Unfortunately for me, that person was my mom; however,…
Medexus Pharmaceuticals (MDP.TO) is a rare disease pharmaceutical company with a portfolio of innovative and high value rare disease products positioning the company for growth in the next decade…
Medexus Pharmaceuticals (MDP.T) today announced its financial results and provided a business update for the three-month period ended June 30, 2021.   “We continued to see pressure on IXINITY® ex-factory…
Medexus Pharmaceuticals (MDP.T) announced today that it has completed enrollment in its Phase 4 clinical trial of IXINITY®, targeting label expansion for pediatric hemophilia B. We are hopeful that…
Medexus Pharmaceuticals (MDP.T) announced today that medac GmbH, the Company’s licensor for treosulfan, has received a Complete Response Letter (CRL) from the Food and Drug Administration (FDA) in response…
Medexus Pharmaceuticals (MDP.T) received Health Canada’s Notice of Compliance to commercialize treosulfan today, according to a press release.   Treosulfan will be sold in Canada using the brand name…